Compass Therapeutics
CMPX
34 hedge funds and large institutions have $164M invested in Compass Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
92% more capital invested
Capital invested by funds: $85.4M → $164M (+$78.6M)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.46% less ownership
Funds ownership: 61.58% → 61.11% (-0.46%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.62M |
| 2 |
FCOMV
Foresite Capital Opportunity Management V
Larkspur,
California
|
+$986K |
| 3 |
O
OrbiMed
New York
|
+$690K |
| 4 |
BlackRock
New York
|
+$355K |
| 5 |
Janus Henderson Group
London,
|
+$334K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$4.12M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$798K |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$730K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
-$586K |
| 5 |
AI
Alphabet Inc
Mountain View,
California
|
-$264K |
CMPX Hedge Fund Activity: Q2 2022 in Review
34 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2022, worth a combined $164M — up 92% from $85.4M a quarter earlier.
Fund positioning in CMPX was balanced in Q2 2022: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 8 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.62M. The largest seller was Consonance Capital Management, cutting an estimated $4.12M.
- 34 institutional investors held Compass Therapeutics (CMPX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $164M of Compass Therapeutics stock for Q2 2022, up 92% quarter-over-quarter.
- 6 funds opened new Compass Therapeutics positions in Q2 2022 and 6 closed out, a net change of 0 holders.
- The largest Compass Therapeutics buyer in Q2 2022 was Adage Capital Partners, an estimated $4.62M added.
- The largest Compass Therapeutics seller in Q2 2022 was Consonance Capital Management, an estimated $4.12M sold.
Based on aggregated 13F filings for Q2 2022.